Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Markman

Showing results (121-130 of 545) with videos related to

Pageof 55
Sort By:
Annals of Internal Medicine|July 4, 2001
Placebo-controlled trialsM Markman
Lancet (London, England)|November 15, 1980
Survival in stage III malignant melanomaM Markman
Lancet (London, England)|November 17, 1984
No increase in allergic reactions with intracavitary administration of cisplatinM Markman
Gynecologic Oncology|December 1, 1994
Follow-up of the asymptomatic patient with ovarian cancerM Markman
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 11, 2008
Strategies to examine new compounds for intraperitoneal use in ovarian cancerM Markman
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 11, 2008
What is the optimal approach to the administration of intraperitoneal chemotherapy in ovarian cancer?M Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1994
Revisiting the debate: the use of new agents in previously untreated patients with small cell lung cancer; quality versus duration of survivalM Markman
Critical Reviews in Oncology/Hematology|January 1, 1985
Intracavitary chemotherapyM Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1993
Phase 1 trials of intensive antineoplastic therapy: a need for a critical reassessment of who should be treatedM Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1993
Cost: the new factor clinical cancer investigators must learn to considerM Markman
Pageof 55

Showing results (121-130 of 545) with videos related to

Sort By:
Pageof 55
Annals of Internal Medicine|July 4, 2001
Placebo-controlled trialsM Markman
Lancet (London, England)|November 15, 1980
Survival in stage III malignant melanomaM Markman
Lancet (London, England)|November 17, 1984
No increase in allergic reactions with intracavitary administration of cisplatinM Markman
Gynecologic Oncology|December 1, 1994
Follow-up of the asymptomatic patient with ovarian cancerM Markman
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 11, 2008
Strategies to examine new compounds for intraperitoneal use in ovarian cancerM Markman
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 11, 2008
What is the optimal approach to the administration of intraperitoneal chemotherapy in ovarian cancer?M Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1994
Revisiting the debate: the use of new agents in previously untreated patients with small cell lung cancer; quality versus duration of survivalM Markman
Critical Reviews in Oncology/Hematology|January 1, 1985
Intracavitary chemotherapyM Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1993
Phase 1 trials of intensive antineoplastic therapy: a need for a critical reassessment of who should be treatedM Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1993
Cost: the new factor clinical cancer investigators must learn to considerM Markman
Pageof 55